Biotech chief delivers commercialisation cure
The News Review:
- Biotech chief delivers commercialisation cure
- Cancer : an invasion in retreat
- Study Finds New Version of QIAGEN’s HPV Test for Developing…
- Edmund Tijerina: Full card planned to remember boxing champ
- Seniors Need More Protein Rich Food To Decrease Muscle Loss Improve…
- South Africa : Aids Focus
Biotech chief delivers commercialisation cure
The Age – Aug 11, 2007
Negotiations aimed at formingpartnerships are under way with other US companies and the companyhas a research alliance with US pharmaceutical giant EliLilly. Treagus born in Cardiff of a Welsh mother and a Cornish fatherparents who migrated to South Africa when he was about 10 yearsold graduated in medicine from the University of Cape Town. “I followed in the footsteps of my grandfather who was acardio-thoracic surgeon but after serving my internship in ahospital in Cape Town I moved to specialise in pharmacology andmoved into the pharmaceutical business in 1991 in Johannesburginitially with Roche in the biotech side of their business as amedical adviser in clinical research” he says. After several yearswith Roche he joined the South African branch of US drug companyWyeth as its medical director for South Africa. “Part of my function at Wyeth was to train sales representativesin product knowledge and I struck up a good rapport with the salespeople. That led to my appointment as sales director for southernAfrica which was a real lateral move for a medico. “That was a defining point for me; I came to understand thatselling was about building relationships and rapport and it got meinvolved in the commercial side of the business.
Cancer : an invasion in retreat
Inserm – Aug 11, 2007
It provides confirmation of biological research results particularly in terms of genetic factors and supplies essential tools for clinical research: large-scale trials prognostic or survival studies quality of life studies assessment of diagnostic methods and the role of risk factors. An ethical framework is indispensable for all these studies. Many advances have been made in our understanding of the fundamental mechanisms of cancer. These open possibilities of.
Study Finds New Version of QIAGEN’s HPV Test for Developing…
presseportal.de – Aug 11, 2007
An economic modeling analysis found that the”FastHPV” test which is being developed specifically for cervicalcancer screening in countries such as China and India could reducethe incidence of cervical cancer by as much as 56 percent if givenjust three times over a woman’s life and combined with appropriatetreatment. In addition a clinical research study concluded that theFastHPV test produces rapid accurate results yet is also simple torun requires minimal infrastructure and will be affordable forpublic-health programs in those countries. FastHPV — a molecular test for cancer-causing types of HPV (humanpapillomavirus) — is under development by QIAGEN N. (Nasdaq: QGEN;Frankfurt Prime Standard: QIA) in partnership with PATH. The test –on track to be submitted for its first regulatory approvals incountries like China and India in 2008 — is specially designed toallow women in areas with scarce healthcare resources to benefit fromthe advanced technology of HPV testing.
Edmund Tijerina: Full card planned to remember boxing champ
San Antonio Express – Aug 11, 2007
They’re also playing at a preregistration party Saturday at Jack’s Lounge on San Pedro near Jackson-Keller. Now here’s why this visiting band is significant: Percussionist Juan Saucedo is one of Quiroga’s cousins. Not stopping When Cedra Clinical Research opened its new facility on the Northeast Side it filled two floors in an office park building — but left the third floor open. The company’s CE David B. Garcia (not the former district clerk or city councilman) said that’s because they expect to grow into it soon. The company threw a grand opening shindig Wednesday to mark its expansion from Austin. Right now the company’s first project is conducting clinical trials on generic medications to make sure they work as well as the name brands.
Seniors Need More Protein Rich Food To Decrease Muscle Loss Improve…
Medical News Today – Medical News Today (press release) – Aug 11, 2007
—————————-UTMB rehabilitation sciences postdoctoral fellow T. Brock Symons was lead author on the paper titled “Aging does not impair the anabolic response to a protein-rich meal. ” ther authors include UTMB research nurse Scott Schutzler clinical research coordinator Tara Cocke Associate Professor David L. Chinkes and University of Arkansas professor Robert R. Pepper lder Americans Independence Center.
South Africa : Aids Focus
News24.com – Aug 11, 2007
Further analysis showed that those who received the vaccine had a higher rate of infection than those who received a placebo said US pharmaceutical giant Merck which helped develop the vaccine. The study volunteers who received the vaccine are being advised of their potentially increased susceptibility Merck said. "We are analysing the data to try to determine if the results are due to immune responses induced by the vaccine differences in study populations or some other biological phenomenon we don't yet understand or simply due to chance" said Keith Gottesdiener vice president of Merck's vaccine and infectious disease clinical research. "It will take some time before we understand why the vaccine did not work and why there was a trend toward more cases of infection in volunteers who received the vaccine" he said in a statement. The experimental vaccine cannot cause infection Merck said. It was a modified cold virus used to deliver three synthetically produced HIV genes in the hopes of stimulating a response from the immune system. The randomised double-blind trials were conducted in various sites in North America South America the Caribbean Australia and South Africa.
Written by admin on August 11th, 2007 with
no comments.
Read more articles on News.